By midmorning, shares had soared 18.2% to $2.60.
Trading volume of 14.2 million exceeded its three-month daily average of 11.7 million.
Earlier, the radioisotope specialist announced it would host a booth at the Annual Meeting of the American Brachytherapy Society (ABS), a conference held in San Diego from April 3 to 5.
IsoRay's Cesium-131 will be featured in five separate panels where specialists, including the University of Pittsburgh Medical Center's Dr. Ron Benoit, Dr. Sushil Beriwal and Dr. Ryan P. Smith, will discuss their experience using the treatment.
"Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used," said CEO Dwight Babcock in a statement.
"With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients," he continued.
Cesium-131 seeds, sutured seeds, stranded mesh or IsoRay's GliaSite radiation therapy system allows physicians to concentrate radiation in required areas, meaning the treatment is less likely to damage surrounding healthy tissue.